Martin Borch Jensen works to industrialize longevity through therapeutic discovery and field-building. He is co-founder and chief scientific officer of Gordian Biotechnology, where he develops in vivo screening approaches for diseases of aging, and founder and president of Norn Group, which advances longevity research through funding, talent development, and strategic coordination. He previously conducted academic research on aging biology, including DNA repair, mitochondrial function, NAD metabolism, and cellular stress responses.
Martin Borch Jensen works to industrialize longevity through therapeutic discovery and field-building. He is co-founder and chief scientific officer of Gordian Biotechnology, where he develops in vivo screening approaches for diseases of aging, and founder and president of Norn Group, which advances longevity research through funding, talent development, and strategic coordination. He previously conducted academic research on aging biology, including DNA repair, mitochondrial function, NAD metabolism, and cellular stress responses.
Career
Martin Borch Jensen studied at University of Copenhagen / National Institute on Aging (Ph.D. research in aging biology).